Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
Harvard Business School
Johnson and Johnson
AstraZeneca

Last Updated: February 1, 2023

Details for New Drug Application (NDA): 022037


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 022037 describes INTUNIV, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the INTUNIV profile page.

The generic ingredient in INTUNIV is guanfacine hydrochloride. There are seven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the guanfacine hydrochloride profile page.
Summary for 022037
Tradename:INTUNIV
Applicant:Takeda Pharms Usa
Ingredient:guanfacine hydrochloride
Patents:1
Pharmacology for NDA: 022037
Mechanism of ActionAdrenergic alpha2-Agonists
Medical Subject Heading (MeSH) Categories for 022037
Suppliers and Packaging for NDA: 022037
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037 NDA Takeda Pharmaceuticals America, Inc. 54092-513 54092-513-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-513-02)
INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037 NDA Takeda Pharmaceuticals America, Inc. 54092-515 54092-515-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-515-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 1MG BASE
Approval Date:Sep 2, 2009TE:ABRLD:Yes
Patent:See Plans and PricingPatent Expiration:Jan 4, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 2MG BASE
Approval Date:Sep 2, 2009TE:ABRLD:Yes
Patent:See Plans and PricingPatent Expiration:Jan 4, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 3MG BASE
Approval Date:Sep 2, 2009TE:ABRLD:Yes
Patent:See Plans and PricingPatent Expiration:Jan 4, 2023Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 022037

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-002 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-001 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-003 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-004 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-003 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-002 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-004 Sep 2, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Mallinckrodt
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.